Voyager Therapeutics reports fourth quarter and full year 2017 financial results
Voyager Therapeutics reported a GAAP net loss of $70.7 million, or $2.64 per share, for the 2017 full year, versus a net loss of $40.2 million, or $1.59 per share, in 2016. Cash, cash equivalents, and marketable debt securities as of Dec. 31, 2017 were $169.1 million. March 14, 2018